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Mass Spectrometry–Based Hepcidin Measurements
in Serum and Urine: Analytical Aspects and
Clinical Implications
Erwin H.J.M. Kemna,1* Harold Tjalsma,1 Vladimir N. Podust,2 and
Dorine W. Swinkels1
Background: Discovery of the central role of hepcidin
in body iron regulation has shed new light on the
pathophysiology of iron disorders. Information is lack-
ing on newer analytical approaches to measure hepcidin
in serum and urine. Recent reports on the measurement
of urine and serum hepcidin by surface-enhanced laser-
desorption/ionization time-of-flight mass spectrometry
(SELDI-TOF MS) necessitate analytical and clinical
evaluation of MS-based methodologies.
Methods: We used SELDI-TOF MS, immunocapture,
and tandem MS to identify and characterize hepcidin in
serum and urine. In addition to diagnostic application,
we investigated analytical reproducibility and biologi-
cal and preanalytical variation for both serum and urine
on Normal Phase 20 and Immobilized Metal Affinity
Capture 30 ProteinChip arrays. We obtained samples
from healthy controls and patients with documented
iron-deficiency anemia, inflammation-induced anemia,
thalassemia major, and hereditary hemochromatosis.
Results: Proteomic techniques showed that hepcidin-20,
-22, and -25 isoforms are present in urine. Hepcidin-25 in
serum had the same amino acid sequence as hepcidin-25
in urine, whereas hepcidin-22 was not detected in se-
rum. The interarray CV was 15% to 27%, and interspot
CV was 11% to 13%. Preliminary studies showed that
hepcidin-25 differentiated disorders of iron metabolism.
Urine hepcidin is more affected by multiple freeze-thaw
cycles and storage conditions, but less influenced by
diurnal variation, than is serum hepcidin.
Conclusion: SELDI-TOF MS can be used to measure
hepcidin in both serum and urine, but serum requires a
standardized sampling protocol.
© 2007 American Association for Clinical Chemistry
The iron-regulating peptide hepcidin is produced by
hepatocytes and secreted into plasma (1–3). Increased
iron stores and inflammation induce hepcidin expression
(3 ), whereas suppression occurs during hypoxia and
anemia (4 ). Although recognition of the central role of
hepcidin in body iron regulation has increased our un-
derstanding of the pathophysiology of iron disorders
(5, 6), few investigative tools are available; these include
an immunodot method for measuring urinary hepcidin
(7 ) and a urinary hepcidin assay based on surface-en-
hanced laser-desorption/ionization time-of-flight mass
spectrometry (SELDI-TOFMS)3 for differentiating various
disorders of iron metabolism (8 ). A SELDI-TOF MS–
based serum assay is under development for measuring
hepcidin in serum (9 ), but this method requires optimi-
zation and evaluation to facilitate clinical investigation of
hepcidin measurement in serum compared with urine
and the biological variation of hepcidin in body fluids. In
this study, we used SELDI-TOF MS, immunocapture, and
tandemMS to identify and characterize hepcidin in serum
and urine.
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Study participants included a control population of
healthy volunteers (laboratory personnel), hereditary
hemochromatosis (HFE4 C282Y homozygous) patients
cross-sectionally selected from a family screening pro-
gram (various stages of phlebotomy treatment), iron
deficiency anemia patients (Hb 8.3 mmol/L men, 7.3
mmol/L women; mean corpuscular volume 80 fL; fer-
ritin 10 g/L), and thalassemia major patients treated
with chelation therapy. The patients were recruited by
their physicians during outpatient clinic visits (all in
Radboud University NijmegenMedical Centre, Nijmegen,
The Netherlands, except for the thalassemia major pa-
tients, who were in Ospedale Sant’Eugenio, Rome, Italy).
Endotoxemia samples from volunteers injected with lipo-
polysaccharide were selected from a human endotoxemia
project (10 ). Written informed consent was obtained from
all study participants, according to the Declaration of
Helsinki. Characteristics of the study participants are
shown in Table 1. In addition, collaborators from sev-
eral medical centers in The Netherlands provided urine
and serum samples from 3 patients with distinct forms
of hereditary hemochromatosis not associated with the
hemochromatosis (HFE) gene [Online Mendelian In-
heritance in Man (OMIM) type 2a, homozygous G320V
HJV variation (11 ); OMIM type 4, N144H-caused ferro-
portin disease (12 )]. Characteristics of these patients are
shown in Table 1 in the Data Supplement that accompa-
nies the online version of this article at http://www.
clinchem.org/content/vol53/issue4.
We collected samples randomly between December
2005 and June 2006, at no specified time of day, except
from the endotoxemia patients, from whom samples were
collected according to a tight time schedule (10, 13). Urine
and blood samples were centrifuged immediately after
collection, divided into aliquots to avoid multiple freeze-
thaw cycles, and stored at 80 °C. We performed the
hepcidin assay within 2 months after collection.
laboratory measurements
Using an Abbott Aeroset analyzer, we measured total
serum iron and latent iron binding capacity by the ascor-
bate/FerroZine colorimetric method, urine creatinine by
enzymatic/colorimetric detection (Roche Diagnostics),
and C-reactive protein by immunologic agglutination
detection with latex-coupled polyclonal anti–C-reactive
protein antibodies (Abbott Laboratories). We quantified
serum ferritin by a solid-phase, 2-site chemiluminescent
immunometric assay (Immulite 2000 and 2500, Diagnostic
Products Corp.) and routine hematology characteristics
by use of a Sysmex XE-2100 analyzer.
seldi-tof ms
We performed nonblinded hepcidin measurements by
use of SELDI-TOF MS as previously reported (8 ). In brief,
a 5-L sample was applied to Immobilized Metal Affinity
Capture 30 (IMAC30), Normal Phase 20 (NP20), or cation
exchange ProteinChip arrays (CM10), all equilibrated
with appropriate buffers according to the manufacturer’s
instructions (Ciphergen Biosystems). Loaded arrays were
incubated in a humidity chamber for 30 min and then
washed according to the manufacturer’s instructions and4 Human gene: HFE, hemochromatosis.
Table 1. Characteristics of participants who provided sample material for assay validation.a
Control Endotoxemia (model) Iron deficiency anemia Thalassemia majorb
Hereditary
hemochromatosisc
n 20 28 6 5 14
Sex (male:female) 9:11 NAd 3:3 1:4 10:4
Age, years 44 (24–62) NA 47 (14–61) 35 (25–44) 56 (23–82)
Hemoglobin, mmol/L 8.7 (7.8–11.0) NA 6.7 (5.0–8.3) 6.3 (6.1–7.3) 9.3 (7.5–12.0)
MCV, fL 88 (84–93) NA 77 (76–79) 86 (78–88) 90 (83–95)
Serum iron (Fe), mol/L 19 (9–38) 18 (7–38) 6 (4–7) 52 (47–62) 22 (10–48)
Fe/TIBC, TS, % 35 (14–73) 40 (23–79) 8 (5–10) 98 (93–100) 56 (21–100)
Ferritin, g/L 60 (11–191) 120 (31–233) 6 (6–10) 784 (272–1710) 64 (28–1361)
C-reactive protein, mg/L 5 9 (5–33) 5 5 5
Urinary hepcidin-25 (NP20),
M Int/mmol Cr
0.52 (0.09–2.97) 6.16 (1.27–19.78) 0.01 (0.01–0.02) 0.21 (0.04–0.98) 0.15 (0.02–1.25)
Urinary hepcidin-25 (IMAC30),
M Int/mmol Cr
1.45 (0.52–7.83) 12.97 (1.95–30.81) 0.10 (0.01–0.19) 0.59 (0.24–2.96) 0.66 (0.08–4.50)
Serujm hepcidin-25 (IMAC30),
M Int/L
4.38 (0.58–9.95) 12.69 (4.11–27.33) 0.41 (0.35–0.60) 0.28 (0.18–2.42) 1.60 (0.19–9.39)
a Data are median (range).
b Cross-sectional selection of thalassemia major patients with variable transfusion history and treated with different iron chelators (desferrioxamine and/or
deferiprone).
c Cross-sectional selection of homozygous C282Y patients from family study; 11 patients are under phlebotomy treatment.
d NA, not available; TIBC, total iron binding capacity; M Int/mmol Cr, megaintensity/mmol creatinine.
Clinical Chemistry 53, No. 4, 2007 621
air-dried for 15 min. Finally, 1 L energy-absorbing
matrix (EAM), made up of a 12.5 g/L solution of sinapinic
acid in 500 mL/L acetonitrile (ACN) containing 5 mL/L
trifluoroacetic acid (TFA), was applied twice onto each
spot surface with the use of polymer-free polypropylene
pipette tips and allowed to air-dry for 5 min. Mass-to-
charge (m/z) spectra were generated using a Ciphergen
Protein Biology System IIc TOFmass spectrometer at laser
intensity 180 (NP20 and CM10) or 175 (IMAC30); detector
sensitivity 9; high mass to acquire 50 kDa; optimization
interval 1500 to 10 000 Da. External mass calibration was
performed with a mixture of synthetic human hepcidin-25
peptide (2789.4 Da, Peptides International), hepcidin-22,
and hepcidin-20 (2436.1 and 2191.8 Da, respectively;
kindly provided by E. Nemeth, University of California,
Los Angeles). Peak annotation was performed with Ci-
phergen ProteinChip Software version 3.2.0. From unpub-
lished experiments we found that for serum and urine,
normalization to total ion current (TIC) did not improve
the hepcidin measurements and was therefore not applied
in this study. Urine hepcidin measurements showed a
relationship with TIC and total peptide content, which
was predominated by hepcidin under the applied exper-
imental conditions and instrumental settings (data not
shown). Consequently, normalization of urine hepcidin
values to TIC leads to loss of differentiation between
samples. In contrast, due to the relatively stable protein
content of serum samples, the serum hepcidin concentra-
tions did not significantly change upon normalization to
TIC (unpublished observations). Although the reabsorp-
tion and excretion characteristics of hepcidin are unclear,
we used urinary creatinine to normalize all peak intensi-
ties for hepcidin-25 in urine. Normalization on creatinine
is a prerequisite for comparison of urine hepcidin mea-
surements because it is the best method to correct for the
highly fluctuating concentration differences between
urine samples. Relative concentrations were expressed as
mega-intensity units per millimole of creatinine. Relative
concentrations of serum hepcidin-25 were expressed as
mega-intensity units per liter. Information on the assay
can be found on: www.UMCN.NL/Hepcidin.
purification of peptides from serum and urine
We first fractionated serum samples by use of spin
columns containing Q HyperD F resin (Pall Corp.), eluted
the flow-through fraction by centrifugation, and eluted
bound proteins with buffers of pH 9, 7, 5, 4, and 3. We
analyzed fractions by use of IMAC30 arrays. Every serum
fraction or urine sample was adjusted to final concentra-
tions of 5% ACN and 0.5% TFA and bound to PLRP-S
beads (Polymer Laboratories, Varian). Bound proteins
were eluted with 5%, 10%, 20%, 30%, 40%, 50%, and 60%
ACN solutions containing 0.1% TFA. We detected pro-
teins in eluted fractions by profiling 1 L of each fraction
on an NP20 array using Protein Biology System IIc MS.
identification of peptides by tandem mass
spectrometry
We analyzed peptides of interest for the presence of
disulfide bonds. Aliquots of the 30% ACN fractions were
air-dried on an NP20 array. A solution containing 10
mmol/L dithiothreitol (DTT) in 50 mmol/L ammonium
bicarbonate, and the sample loaded arrays, was preheated
to 70 °C. Then we loaded 10-L aliquots of the DTT
solution onto the spots and air-dried them at 70 °C. After
complete evaporation of solutions and cooling to room
temperature, we applied EAM. We acquired single MS
spectra for unreduced and DTT-reduced samples by use
of a Q-STARXL MS/MS (Applied Biosystems) equipped
with a Ciphergen PCI-1000 ProteinChip Interface. We
used the reduced samples to acquire tandem mass spec-
trometry (MS/MS) spectra. We subjected the ions of
interest (m/z values of 2198 for hepcidin-20, 2442 for
hepcidin-22, and 2796 for hepcidin-25) to collision-in-
duced dissociation and submitted the results to the data-
base-mining tool Mascot (Matrix Science) for peptide
identification.
immunocapture
We captured hepcidin from urinary samples by use of
Protein G coupled to IDM beads (Ciphergen Biosystems)
and polyclonal rabbit antihepcidin serum (generous gift
from E. Nemeth and T. Ganz, University of California, Los
Angeles). We performed all incubation steps at room
temperature. Protein G beads were first incubated with
rabbit antiserum diluted 20 times in 0.01 mol/L phos-
phate-buffered saline (PBS; Sigma-Aldrich Chemie BV)
supplemented with 0.1% Triton X-100 (PBS-Tx). We
washed the beads 3 times with PBS-Tx to remove un-
bound serum proteins and resuspended the beads in
urine, diluted 20 times in PBS containing a final concen-
tration of 0.25 mol/L NaCl and 0.1% Triton X-100 (PBS0.25-
Tx). We washed the beads 6 times with PBS0.25-Tx to
remove unbound and nonspecifically bound proteins.
Finally, we eluted bound proteins with 500 mL/L ACN
containing 3 mL/L TFA. To obtain profiles of Protein
G–captured proteins, we applied eluates to a CM10 array
equilibrated with 0.1 mol/L ammonium acetate (pH 3)
and incubated them for 30 min in a humidity chamber. To
obtain reference spectra, we diluted untreated urine sam-
ples once in equilibration buffer before on-spot incuba-
tion. Spots were washed, allowed to air-dry, and followed
by sinapinic acid application.
analytical assay characteristics
We performed spot-to-spot precision for hepcidin-25 on
NP20 and IMAC30 ProteinChip array with 2 human urine
samples with medium and high hepcidin concentrations.
Both samples were applied onto the first 6 positions of the
8-spot array, followed by addition of the EAM. The last 2
spots were used for control samples. For serum, we
followed the same procedure for a single sample.
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We used the same urine and serum samples for a
chip-to-chip reproducibility study. We collected single
measurements for serum and urine on NP20 and IMAC30
array types from randomized chip positions for 10 days (8
days for serum application on NP20 arrays). Every day a
new sample aliquot was thawed, and freshly prepared
EAM was applied. From these data, we calculated means,
SDs, and CVs.
We measured linearity of peak intensities by dilution
of the urine and serum samples used for the reproduc-
ibility tests with human urine or serum (dilution samples)
from a patient with hepcidin concentrations below those
detectable by SELDI-TOF MS. Immediately before sample
application, we diluted 1 to 18 L sample in a polypro-
pylene microcentrifuge container to a 20 L end volume
with the dilution sample. After pipette mixing, 5 L of the
diluted sample was spotted on the array.
We created standard curves of synthetic hepcidin-25
for both serum and urine applications. After dissolving
the lyophilized peptide in distilled water (100 mol/L),
the peptide was diluted 4500-fold with dilution sample
for serum or urine (22.2 nmol/L). Dilutions of 18, 16, 12,
8, 4, 2, and 1 L of the 22.2 nmol/L solution with the
dilution sample to the final volume of 20 L yielded a
standard curve ranging from 22.2 to 1.11 nmol/L.
preanalytical and biological interferences
We evaluated the influence of multiple freeze-thaw cycles
for both serum and urine using IMAC30 arrays. Five sera
and 4 urine samples from different participants and
different intensity concentrations underwent 4 freeze-
thaw cycles. After every cycle, we analyzed hepcidin
batchwise by single measurement.
We studied the existence of a circadian rhythm for
hepcidin in serum and urine by performing a 24-h time
course in 3 healthy volunteers (1 man, 2 women). Blood
and urine were collected every 3 h for analysis of routine
iron measurements and serum and urine hepcidin
(IMAC30 array), starting at 6:00 AM with fasting blood
and urine samples, after which the fasting state was
ended. All samples were processed as described above
and stored at 80 °C before analysis (batchwise by single
measurement).
statistic analysis
We performed statistical analyses with GraphPad Prism
software, version 4.0. Pearson correlation was used for
comparison studies. P values 0.05 were considered
significant.
Results
hepcidin identification and characterization
The presence of hepcidin-25 in human urine (8 ) and
serum (9 ) has been demonstrated. Our current investiga-
tion revealed that, in addition to hepcidin-25, hepcidin-20
can be verified in both urine and serum with the use of a
purified synthetic reference human hepcidin peptide,
whereas hepcidin-22 can be identified only in urine
(Fig. 1A). This supports the hypothesis that both the 20-
and 25–amino acid peptides are secreted in the circulation
after production in hepatocytes, whereas the 22–amino
acid peptide merely is a urinary degradation product of
hepcidin-25 (14 ).
In addition to mass tracing, we investigated immuno-
capture of all 3 known forms of hepcidin from urine.
Immunoaffinity assays using polyclonal rabbit antihepci-
din antibodies [the same as those used in hepcidin dotblot
assay (7 )] showed that the 3 peaks annotated as hepcidin-
25, -22, and -20 can be specifically captured from a human
urine sample of a healthy individual (Fig. 1B). MS/MS
analysis of peptides in a urine sample from an endotox-
emia patient confirmed that the peaks with m/z of 2198,
2442, and 2796 corresponded to hepcidin-20, -22, and -25,
respectively (see Fig. 1A in the online Data Supplement).
Similarly, we identified the m/z 2796 peak in serum as
hepcidin-25. Notably, single MS spectra of urine and
serum samples displayed a mass shift of 8 Da for all
hepcidin forms after reduction with DTT, as exemplified
for urine hepcidin-25 (see Fig. 1B in the online Data
Supplement). This observation confirms the presence of 4
disulfide bonds in these peptides, which is a typical
characteristic of hepcidin (15 ). Finally, the MS/MS spec-
tra for serum and urine peptides with m/z of 2796
displayed mostly the same fragment ions, strongly sug-
gesting that both parent ions corresponded to the same
peptide hepcidin-25 (see Fig. 1C in the online Data
Supplement).
analysis of serum and urine hepcidin-25 on
np20 and imac30 proteinchip arrays
Because the roles of hepcidin-20 and -22 in iron metabo-
lism are unclear (2, 14), hepcidin-25 is used for optimiza-
tion of serum and urine hepcidin measurements. To
evaluate the effect of ProteinChip array type on the
performance of the hepcidin-25 assay, we analyzed 73
urine and serum sample pairs from controls and patients
with various iron metabolism disorders using the previ-
ously reported NP20 and IMAC30 arrays (8, 9). Although
hepcidin concentrations measured using NP20 arrays are
lower than those measured with IMAC30 arrays, both
arrays correlate for the urinary application (R  0.928, P
0.0001; Pearson correlation; Fig. 2A). Sensitivity was
higher with the use of IMAC30 compared with the NP20
arrays, likely because of highly specific binding of hepci-
din to the IMAC-Cu surface. In contrast to the IMAC30
arrays, NP20 arrays did not bind detectable concentrations
of serum hepcidin-25; therefore, we could not perform
correlation analyses for serum and urine on NP20 arrays. In
contrast, IMAC30 arrays showed a significant correlation
(R  0.822, P 0.0001; Pearson correlation; Fig. 2B).
Chip-to-chip variation of the urine application for
IMAC30 ranged from 22% at a high intensity of 48 to
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27.5% at a lower intensity of 20 (Table 2), whereas NP20
variation reached 34% for the same samples. Precision
was also better for urine hepcidin measurements using
the IMAC30 chip (CVs 11% and 13%) compared with the
NP20 chip (CVs of 16% and 23%; Table 2).
For serum, the reproducibility was strongly affected by
differences in protein binding capacity of both arrays.
Intensities measured from the same sample differed, from
an intensity of 5 with relatively high CVs on NP20 array
to an intensity of 50 with low CVs on IMAC30 array. We
checked the linearity of the urinary and serum hepcidin
application on IMAC30 array by measuring a dilution
series of urine and serum samples from an inflammation
patient (single measurements). Fig. 2, A and B, in the
online Data Supplement shows a high degree of linearity
for both urine and serum (R 0.993 and 0.971, respectively).
Intensity values55 seem to deviate from linearity, perhaps
because of MS detector saturation. Therefore, an intensity
value of 55was considered to be the upper level of detection.
The construction of a calibration curve with synthetic
human hepcidin-25 showed that both NP20 and IMAC30
arrays are capable of producing a 6-point calibration
curve based on a urine matrix (see Fig 2, C and D, in the
online Data Supplement). Again, intensity values 55
deviated from linearity and therefore were considered as
exceeding the upper level of detection. Construction of
Fig. 1. Hepcidin identification and
characterization.
(A), SELDI-TOF MS profiles in serum and
corresponding urine samples from a
participant with an inflammation re-
sponse after lipopolysaccharide injec-
tion. The annotated peak masses
matched to the masses in the reference
peptide mix that contained purified syn-
thetic human hepcidin-20, -22 (E. Nem-
eth, University of California, Los Ange-
les), and -25 (Peptides International).
(B), immunocapture of urine hepcidin.
Urine samples from a healthy individual
were incubated with Protein G beads
loaded with either a polyclonal antihep-
cidin rabbit antibody or control rabbit
IgG. Immunocaptured proteins were an-
alyzed by SELDI-TOF MS, and protein
profiles were compared with the protein
profile of an untreated urine sample
(upper panel). Peaks corresponding to
3 forms of urine hepcidin (8 ) and those
corresponding to rabbit IgGs are indi-
cated. A peak with m/z 2436 that is
present in untreated urine, but not
present in the captured fractions, is
marked (*), as it shows that the capture
of the 3 hepcidin forms was specific.
Notably, on-spot incubation of the same
urine sample with antihepcidin antibod-
ies bound to Protein G-loaded arrays did
not yield detectable hepcidin concentra-
tions (our unpublished observations).
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the same concentration interval on IMAC30 array in a
serum matrix showed hepcidin-25 only for a concentra-
tion of 22.2 nmol/L and above (results not shown).
diagnostic application
We categorized urine and serum sample pairs into 5
groups after clinical diagnosis. Fig. 3 shows that, despite
the variation within each group and a slight overlap,
differentiation between inflammation-induced and iron
deficiency anemia is clear for both serum and urine
hepcidin concentrations measured on IMAC30 array. The
results are comparable with the results obtained with
NP20 and consistent with previous reports (7, 8). The
broad ranges of the thalassemia group and the hemochro-
matosis group are in accordance with the individual
heterogeneity in genetic makeup, extent of anemia, and
treatment (16–18).
In this study, we found serum and urine hepcidin
concentrations close to zero in 2 brothers treated for
juvenile hemochromatosis (OMIM type 2a) and values in
Fig. 2. Detection of serum and urine hepcidin-25 on NP20 and IMAC30
arrays.
Correlation of urinary hepcidin-25 values as measured by NP20 and IMAC30
ProteinChip arrays (A) and coupled serum and urine hepcidin-25 concentrations
measured on IMAC30 array (B). The solid line represents the regression line, and
the dotted line indicates the 95% CI of the regression line. It should be noted that
the apparent increased scatter in absolute variation on high hepcidin values
compared with low values, as presented in panel A of this figure, is because
absolute concentrations are used in this plot. The relative average for the high
values is not more scattered than the low-end values (data not shown), which is
in concordance with the CV values shown in Table 2. As it is currently unknown
whether and how much hepcidin is reabsorbed in the tubulus, we cannot indicate
whether this aspect contributes to the scatter in panel B of this figure.
Table 2. Reproducibility of hepcidin-25 analysis by SELDI-
TOF MS in NP20 and IMAC30 chip arrays in both serum
and urine.
NP20 IMAC30




Mean 2788.48 13.10 2788.65 19.84
SD 0.94 4.37 1.96 5.46
CV, % 0.03 33.4 0.07 27.5
Level II
Mean 2788.37 41.55 2788.45 47.84
SD 0.89 10.00 1.64 10.50
CV, % 0.03 24.1 0.06 22.0
Spot-to-spotb
Level I
Mean 2787.13 15.23 2788.53 17.83
SD 1.00 2.62 1.55 1.97
CV, % 0.04 16.5 0.06 11.0
Level II
Mean 2787.88 40.61 2788.24 40.89
SD 0.53 9.47 1.00 5.25




Mean 2788.40 5.26 2788.02 51.96
SD 1.41 1.73 1.56 7.76
CV, % 0.05 32.9 0.06 14.9
Spot-to-spotb
Level I
Mean 2787.54 4.27 2788.33 43.89
SD 0.60 1.14 0.59 5.06
CV, % 0.02 26.6 0.02 11.5
a Ten-day single measurement with randomized chip position.
b One chip (6 replicates).
c Eight-day single measurement (NP20 array) and 10-day single measurement
(IMAC30 array) with randomized chip position.
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the upper level of the reference range for a patient treated
for ferroportin disease (OMIM type 4; see Table 1 in the
online Data Supplement). These data confirm the poten-
tial of hepcidin analysis in prescreening for the presence
of non-HFE hemochromatosis.
preanalytical and biological determinants
that influence hepcidin-25 measurements in
serum and urine
Decreases in hepcidin concentrations in serum samples
due to multiple freeze-thaw cycles is of minor importance
compared with those in urine (see Fig. 3 in the online
Data Supplement). Preliminary results from urine sam-
ples stored at 80 °C and 20 °C during a 6-month
course showed that (a) hepcidin was stable only at80 °C
and (b) addition of protease inhibitor phenylmethylsulfo-
nyl fluoride (19 ) had no beneficial effect (unpublished
observations).
Hepcidin concentrations in serum follow a clear circa-
dian rhythm, such that the concentrations were 2- to
6-fold higher at 1500 than at 0600. Urinary concentrations,
however, show a more blunted response, and thus less
Fig. 3. Urinary and serum hepcidin-25 concentrations in selected
clinical populations.
Urinary hepcidin-25 concentrations measured on NP20 array (A) and IMAC30
array (B) and serum hepcidin-25 measured on IMAC30 array (C). LPS, volunteers
injected with lipopolysaccharide (6 h after injection); IDA, iron deficiency anemia
patients; TM, thalassemia major patients; HH(YY), C282Y homozygous hemo-
chromatosis patients. Box plots show 25th and 75th percentile with median for
every group. Error bars represent minimum and maximum values. Characteristics
of each population are shown in Table 1. Fig. 4. Circadian influence on urinary and serum hepcidin-25
concentrations.
Urinary and serum hepcidin concentrations and serum iron concentration in 3
healthy volunteers during a 24-h time course (participants A and C, premeno-
pausal women; participant B, man). Circadian influence is seen on all 3
variables. Individual differences are visible on amplitude and frequency pattern
and relative concentration difference between urinary and serum hepcidin. Note
that in participant A, C-reactive protein concentrations increased to 10 mg/L in
the last 6 h of the time course, which suggests that an inflammatory process
may have contributed to the persistent increase in hepcidin and the decrease in
serum iron during this period.
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diurnal variation. The course of serum iron shows an
inverse association with serum and urine hepcidin values
(Fig. 4).
Discussion
The IMAC30 array–based urinary hepcidin assay corre-
lated significantly with the previously described urinary
hepcidin MS application using NP20 arrays (8 ) and
showed greater sensitivity and reproducibility, resulting
in improved analytical performance. The increase in pro-
tein-binding capacity of the IMAC30 array makes it
particularly suitable for serum analysis and measurement
of low hepcidin concentrations in urine.
The total assay variation includes analytical variation,
biological or diurnal variation, and preanalytical varia-
tion, all contributing to the widening of ranges of the
clinical utility clusters. In the future, we plan to routinely
perform duplicate measurements and investigate isotope
dilution (20 ) or hepcidin derivatives as internal standards
to reduce analytical variability.
Biological variation in hepcidin concentrations due to a
circadian rhythm correlated inversely with daily varia-
tions in serum iron concentrations (21 ), in accordance
with previous reports that transferrin receptors 1 and 2
on the outer hepatocyte membrane act as sensors of
circulating iron and TS, thereby linking low serum iron
with increased hepcidin synthesis (22, 23). Circadian
rhythm may also lead to important variation in outcome
if sampling time is not standardized, thereby contribu-
ting to the wide variation in hepcidin concentrations of
the control population (Fig. 3C). Sampling according to
protocol led to decreased variation in hepcidin concentra-
tions within the lipopolysaccharide group. The low vari-
ation within the iron deficiency anemia group is likely to
be due to the dominant down-regulating influence of an
iron-deficient erythropoiesis on hepcidin that prevents
circadian increases.
Variation in hepcidin results is also attributable to
preanalytical conditions. According to our preliminary
results, urine samples are more susceptible than serum to
variation from multiple freeze-thaw cycles, which should
be avoided, and urine samples should be stored at80 °C
as soon as possible (24, 25).
Measurement of serum and urine hepcidin by the same
technique, and under the same circumstances, enabled
comparison of serum with urinary values. Although their
association was strong, confirming the previously re-
ported correlation between hepcidin mRNA expression in
liver cells and urinary hepcidin excretion (26 ), differences
in serum and urine composition prohibit absolute com-
parison of analytical characteristics such as binding com-
petition on the array surface and flight behavior during
SELDI-TOF MS analysis (27 ). Aspects such as ionization
efficiency or ion suppression also can play a role and
should be investigated in future studies. Meanwhile,
differences in specimen behavior preclude calculations of
the kinetics of hepcidin release by hepatocytes and its
excretion from the blood into the urine. Construction of a
calibration curve by addition of the same amount of
hepcidin-25 to serum or diluted urine confirms this effect,
leading to speculation that a binding protein in serum
prevents the binding of free hepcidin on the chip surface
at low concentrations (27 ). To circumvent differences in
binding characteristics or possible matrix interferences,
methodologic approaches such as plasma fractionation (27)
or the use of magnetic reversed-phase beads (28) have to be
investigated for utility on hepcidin measurements.
Our reported SELDI-TOF MS method detected all 3
isoforms of hepcidin, improved urinary hepcidin analysis,
and enabled measurement of serum hepcidin by IMAC30
array. We show for the first time a high correlation of
concentrations measured in corresponding serum and
urine samples. Selection of the optimal body fluid for
analysis, however, is influenced by preanalytical, ana-
lytical, and biological variations that effect serum and
urine differently. Urine is more vulnerable to multiple
freeze-thaw cycles and storage temperatures other than
80 °C but less influenced by diurnal variation. Serum
is more susceptible to circadian variation, and therefore
standardization of sampling time is needed in clinical
studies with serum. Serum is likely to be more sensitive
than urine, however, for monitoring short-term kinetics
of body hepcidin concentrations. Therefore, the speci-
men of first choice depends on study design and prac-
tical aspects such as availability of materials and equip-
ment. The ability to measure hepcidin in both serum and
urine confirms that the learning process on hepcidin
characteristics, kinetics, and clinical utility has only just
begun.
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